Despite weak revenue forecasts, the company's P/S ratio rema...
Despite weak revenue forecasts, the company's P/S ratio remains high, which could lead to significant investment risk if the high P/S ratio drops.
Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 28% Share Price Plunge Could Signal Some Risk
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3379Followers
0Following
8173Visitors
Follow